SGHTHealthcare · Medical DevicesThe 8 Wall Street analysts covering Sight Sciences, Inc. hold a median 12-month price target of $9.5 — +2.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Sight Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (99): The shares have been drifting up relative to others.
Volatility (19): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SGHT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2.0% from it.
Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 Oct 2026 | HC Wainwright & Co. | Initiates | Buy | $14 |
| 5 Oct 2026 | Citigroup | Maintains | Neutral | $8.00 → $10 |
| 5 Oct 2026 | Citigroup | Maintains | Neutral | — |
| 17 Aug 2026 | Citigroup | Maintains | Neutral | — |
| 6 Aug 2026 | UBS | Maintains | Buy | $7.00 → $8.00 |
| 6 Aug 2026 | UBS | Maintains | Buy | — |
| 28 July 2026 | UBS | Assumes | Buy | $11 → $7.00 |
| 8 July 2026 | Citigroup | Maintains | Neutral | $5.15 → $6.00 |
| 8 July 2026 | Citigroup | Maintains | Neutral | — |
| 28 May 2026 | Citigroup | Maintains | Neutral | — |
| 6 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 6 Mar 2026 | UBS | Maintains | Buy | — |
| 2 Mar 2026 | Stifel | Maintains | Buy | — |
| 5 Jan 2026 | Piper Sandler | Upgrade | Overweight | — |
| 23 Dec 2025 | UBS | Maintains | Buy | — |
| 11 Dec 2025 | Citigroup | Maintains | Neutral | — |
| 10 Dec 2025 | Lake Street | Maintains | Buy | — |
| 2 Dec 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 10 Nov 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 7 Nov 2025 | Piper Sandler | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SGHT appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Sight Sciences, Inc. returned +83.3% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 95% of US stocks
Cheaper than 20% of US stocks
Cheaper than 9% of US stocks
Cheaper than 91% of US stocks
Higher than 68% of US stocks
Higher than 59% of US stocks
Higher than 97% of US stocks
Higher than 22% of US stocks
Higher than 12% of US stocks
Higher than 22% of US stocks
Higher than 26% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Sight Sciences, Inc. has a market value of $512.9M and an enterprise value of $489.4M.
Revenue in the twelve months to 30 June 2026: $83.4M. The latest quarter grew 19.5% year on year.
Net income over the same four quarters: −$29.8M, a −35.7% net margin.
Diluted earnings per share, trailing twelve months: $−0.56.
Free cash flow in the twelve months to 30 June 2026: −$23.3M.
Trailing P/E: −12.6×; forward P/E: −23.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Sight Sciences, Inc. employs 186 people — $448K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Sight Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research says Sight Sciences has a combination of factors that may support an earnings beat in its upcoming report and highlights key expectations.
Why it matters — SGHT watchers may find the item relevant for its discussion of expectations ahead of the company's upcoming earnings report.
Sight Sciences announced it will report third-quarter 2026 financial results after market close on November 4, 2026. Management will discuss the results on a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Why it matters — SGHT watchers can note the scheduled date and time for the company's quarterly results and management discussion.
Sight Sciences shares gained Thursday after H.C. Wainwright initiated coverage with a Buy rating and a $14 price forecast.
Why it matters — The new analyst coverage and its rating accompanied the stock's Thursday gain.
Seeking Alpha describes Sight Sciences as showing progress, citing 20% Q2 revenue growth, dry eye business acceleration, improved gross margins, reduced cash burn, Aetna coverage for 25 million insured lives, and product updates. It also notes liquidity pressures and continuing reimbursement, procedure-cost, utilization, and surgeon-preference challenges.
Why it matters — The mixed developments matter to SGHT watchers because adoption tailwinds and operating improvements are tempered by persistent reimbursement and utilization hurdles.
Sight Sciences announced the commercial availability of the OMNI Ultra Surgical System, an expansion of its ab interno canaloplasty platform, and will debut the technology at the 2026 American Academy of Ophthalmology annual meeting in New Orleans, October 9-12.
Why it matters — The commercial launch and featured debut of a new technology at a major industry conference signals continued expansion of Sight Sciences' core surgical platform, which is relevant to SGHT watchers.
The 8 Wall Street analysts covering Sight Sciences, Inc. have a median 12-month price target of $9.5, with estimates ranging from $8 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Sight Sciences, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Sight Sciences, Inc. 88 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Sight Sciences, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (99 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +2.0% from the last close, and Ticker Nerd's factor model ranks Sight Sciences, Inc. 88 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Sight Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SGHT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $14 over the next 12 months.
Sight Sciences, Inc. returned +83.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing interventional technologies for glaucoma and dry eye disease.
The most recent item we track (Zacks Investment Research, 28 Oct 2026): "Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?". Zacks Investment Research says Sight Sciences has a combination of factors that may support an earnings beat in its upcoming report and highlights key expectations.
Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing interventional technologies for glaucoma and dry eye disease. Its current product portfolio includes the OMNI Surgical System family for minimally invasive glaucoma procedures, the SION Surgical Instrument for trabecular meshwork excision, and the TearCare System for treating evaporative dry eye associated with meibomian gland dysfunction. The company serves eyecare providers, including ophthalmologists and optometrists, by offering tools designed to address key causes of intraocular pressure buildup and tear-film dysfunction. Sight Sciences operates through its Surgical Glaucoma and Dry Eye segments, positioning its products across procedural eyecare settings where device-based treatment options are used to support patient care. Headquartered in Menlo Park, California, Sight Sciences plays a focused role in the medical technology market by supplying specialized devices for prevalent eye conditions.
CEO Mr. Paul Badawi · 186 employees · United States · https://www.sightsciences.com
